Please wait while we load the price list

Men’s Health Advisor - Alpha blockers

November 19th, 2008

Alpha blockers–specifically selective alpha blockers such as tamsulosin (Flomax) and alfuzosin (Uroxatral)–have become the front-line treatments for many people with benign prostatic hyperplasia (BPH), or enlarged prostate, according to Eric Klein, M.D., head of the Section of Urologic Oncology at The Cleveland Clinic’s Glickman Urologic Institute. However, since BPH a…

Medical Marketing and Media - At work with… Stephen Neale

November 15th, 2008

Q: What was your biggest break?
My big break came when I attached a clothespin to a water balloon. Voila! The Hytrin ad.
Q: What’s the worst part of your job?
The routine - or the threat of the routine.
Q: Who do you admire most in advertising?
The person who can do what I can’t. That would be a great copywriter.
Q: What is the view outside your office?
The Hotel Monaco. Shows start at 1 p.m., …

Business Wire - Mylan Announces Approvals

November 13th, 2008

Business &Medical Editors
PITTSBURGH–(BUSINESS WIRE)–Feb. 17, 2000
Mylan Laboratories Inc. (NYSE:MYL) announced today that it has received final approval to manufacture and market Terazosin Hydrochloride Capsules in 1mg, 2mg, 5mg, and 10mg strengths.
Terazosin is the generic equivalent to Hytrin(R), an alpha-1…

M2 Presswire - FTC charges drug manufacturers with stifling competition in two prescription drug markets; Complaint filed against Hoechst Marion Roussel, Inc. and Andrx…

November 8th, 2008

Related Results

Boehringer, Abbott to co-promote Flomax - Brief Article

At work with… Stephen Neale

American Family Physician - Medical treatment of benign prostatic hyperplasia

November 1st, 2008

Clinical Question
What is the best medical therapy for benign prostatic hyperplasia (BPH)?
Evidence-Based Answer
Although alpha blockers and 5-alpha reductase inhibitors each reduce BPH symptoms more than placebo (Strength of Recommendation [SOR]: A), alpha blockers are more effective than 5-alpha re…

Daily Herald (Arlington Heights, IL) - FTC chides Abbott Lab for generic drug deal.(Business)

October 31st, 2008

Abbott Laboratories received a scolding from the U.S. Federal Trade Commission on Thursday for paying another drug maker to keep a generic version of its hypertension drug, Hytrin, off the market. The consent order approved by the commission Thursday includes…

Medical Marketing and Media - Court blocks FDA regulation, this time on generic drugs

October 28th, 2008

Another FDA regulation was struck down by the U.S. district court in Washington, this time covering the approval process for generic drugs.
Under the law, the first manufacturer to seek approval of a generic drug from the FDA gets a 180-day period of exclusive rig…

Drug Store News - FTC suit charges drug companies with stifling generic competition - Brief Article

October 24th, 2008

The Federal Trade Commissions suit filed last month alleging anticompetitive practices by Aventis and Andrx Corp. is part of a larger year-long investigation involving six drugs poised to lose patent protection.
The FTC suit charges that Hoechst, now Aventis, and Andrx entered an…

Drug Store News - Teva USA introduces Terazosin hydrochloride capsules

October 21st, 2008

Teva Pharmaceuticals USA has introduced Terazosin HCl capsules, 1 mg, 2 mg, 5 mg and 10 mg. The product, indicated for treatment of benign prostatic hyperplasia as well as hypertension, is bioequivalent to and therapeutically interchangeable with Hytrin (terazosin HCl) capsules. All capsule strengths are available in bottles of 100.

Most Popular
Public Speaking: 7 Secrets Of Great Publ…

Topeka Capital-Journal, The - Lawsuit says companies delayed generic version of drug

October 18th, 2008

The Capital-Journal
Kansas consumers who purchased the brand name prescription medication Hytrin are eligible for refunds from a $30.7 million nationwide settlement announced Friday.
The refunds to consumers and third-party payers in 18 states will be paid by two companies that, according to the antitrust complaint, had conspired to engage in anticompetitive conduct that delayed the availability of a more affordable generic version of the medication.
Hytrin…